Companies don’t plan to fail when it comes to recruitment, but many fail to plan. What happens if your marketing director resigns? A recruiting plan gives your organization the confidence in knowing that whatever happens, there is a process in…
HOME > ORGANIZATION
ORGANIZATION
- JPMA Positive on Use of Clinical Research Data in Submissions, but Wary of Funding Database
May 26, 2021
- Ken Suzuki Likely to Come Back as JPWA Chief after 2 Years
May 25, 2021
- JPMA Will Work towards Price Maintenance for On-Patent Medicines: New President
May 24, 2021
- Eisai’s Okada Elected as JPMA Chief, Daiichi Sankyo’s Manabe to Head FPMAJ
May 21, 2021
- JPMA Has “Different View” from US Govt on COVID-19 Vaccine IP Waiver
May 10, 2021
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
- Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
April 16, 2021
- Plaintiffs of HPV Vaccine Suits Urge LDP Group to Hear Stories of Sufferers
April 16, 2021
- Scandals Making It Difficult to Recommend Generics to Members: Kyokai Kenpo Chair
April 16, 2021
- Govt Should Set API-by-API Targets for Biosimilars: Society Chief
April 15, 2021
- Hold Off on Nichi-Iko Products for Now to Remove Generic Distrust: Pharmacy Chief
April 9, 2021
- Wakayama Council Makes List of 500 Drugs Commonly Used in Region, Snubs Nichi-Iko/Kobayashi Kako Generics
April 9, 2021
- Industry Group Rolls Out Barcode Reader App for E-Labeling
April 8, 2021
- Generic Industry Group Requests Blanket Manufacturing Checkups for 39 Member Firms
March 31, 2021
- 27.2% Pharmacists Want Total Product Switch from Nichi-Iko to Other Makers, 56.6% Hoping Partial Switch: Survey
March 31, 2021
- Generic Use Rate at 79.4% in October-December 2020: JGA
March 29, 2021
- Industry Group Poised for Pilot Rollout of E-Labeling App in April, Looks to Sales Reps for Popularization
March 26, 2021
ページ
Is policy intervention necessary for Japanese drug makers reliant on off-patent brand-name medicines? Many members of the health ministry’s key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
The Liberal Democratic Party (LDP) will wrap up its discussions on the FY2023 tax reform plan within a few days. Some provisions of the R&D tax credit system, which allow drug makers to deduct a portion of R&D expenses from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…